FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Amerisource Health Services Duloxetine Delayed-Release Capsules Recall

Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, 90 count bottles, Manufacture…

Amerisource Health Services LLC · Columbus, OH

Risk level
Class II
Reported by FDA
Jan 1, 2025
Recall ID
D-0156-2025
Check your lot numberHow we source this data

Summary

Amerisource Health Services recalled Duloxetine Delayed-Release Capsules starting Dec 6, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0156-2025 on Jan 1, 2025. Reason: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit. Status: Ongoing.

Why it was recalled

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

Product description

Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, 90 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-414-05

Lot numbers, UPCs & expiration codes

Lot DT3023030A Exp 2/28/2025

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0156-2025
Classification
Class II
Status
Ongoing
Recall initiated
Dec 6, 2024
FDA report date
Jan 1, 2025
Quantity
13,678 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Amerisource Health Services LLC

Original FDA data

Every field from FDA enforcement report D-0156-2025, exactly as published.

Show all FDA fields
City
Columbus
State
OH
Status
Ongoing
Country
United States
Event ID
95953
Address
2550 John Glenn Ave Ste A
Code information
Lot DT3023030A Exp 2/28/2025
Postal code
43217-1188
Report date
Jan 1, 2025
Product type
Drugs
Recall number
D-0156-2025
Classification
Class II
Recalling firm
Amerisource Health Services LLC
Product quantity
13,678 bottles
Reason for recall
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx only, 90 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-414-05
Distribution pattern
Nationwide in the USA
Recall initiation date
Dec 6, 2024
Initial firm notification
Letter
Center classification date
Dec 23, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0156-2025, published Jan 1, 2025. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls